Shengpeng Liu1,2, Jerry J Flores2, Bo Li1, Shuixiang Deng2,3, Gang Zuo2, Jun Peng2, Jiping Tang2, John H Zhang2,4. 1. Department of Pediatrics, Shenzhen People's Hospital, the Second Clinical Medical College of Jinan University, Shenzhen, Guangdong, China. 2. Department of Physiology and Pharmacology, Loma Linda University School of Medicine, Loma Linda, California, USA. 3. Department of Critical Care Medicine, Huashan Hospital, Fudan University, 12 Middle WuLuMuQi, Shanghai, China. 4. Departments of Anesthesiology, Neurosurgery and Neurology, Loma Linda University School of Medicine, Loma Linda, California, USA.
Abstract
AIMS: Blood clots play the primary role in neurological deficits after germinal matrix hemorrhage (GMH). Previous studies have shown a beneficial effect in blood clot clearance after hemorrhagic stroke. The purpose of this study is to investigate interleukin-19's role in hematoma clearance after GMH and its underlying mechanism of IL-20R1/ERK/Nrf2 signaling pathway. METHODS: A total of 240 Sprague-Dawley P7 rat pups were used. GMH was induced by intraparenchymal injection of bacterial collagenase. rIL-19 was administered intranasally 1 hour post-GMH. IL-20R1 CRISPR was administered intracerebroventricularly, or Nrf2 antagonist ML385 was administered intraperitoneally 48 hours and 1 hour before GMH induction, respectively. Neurobehavior, Western blot, immunohistochemistry, histology, and hemoglobin assay were used to evaluate treatment regiments in the short- and long-term. RESULTS: Endogenous IL-19, IL-20R1, IL-20R2, and scavenger receptor CD163 were increased after GMH. rIL-19 treatment improved neurological deficits, reduced hematoma volume and hemoglobin content, reduced ventriculomegaly, and attenuated cortical thickness loss. Additionally, treatment increased ERK, Nrf2, and CD163 expression, whereas IL-20R1 CRISPR-knockdown plasmid and ML385 inhibited the effects of rIL-19 on CD163 expression. CONCLUSION: rIL-19 treatment improved hematoma clearance and attenuated neurological deficits induced by GMH, which was mediated through the upregulation of the IL-20R1/ERK/Nrf2 pathways. rIL-19 treatment may provide a promising therapeutic strategy for the GMH patient population.
AIMS: Blood clots play the primary role in neurological deficits after germinal matrix hemorrhage (GMH). Previous studies have shown a beneficial effect in blood clot clearance after hemorrhagic stroke. The purpose of this study is to investigate interleukin-19's role in hematoma clearance after GMH and its underlying mechanism of IL-20R1/ERK/Nrf2 signaling pathway. METHODS: A total of 240 Sprague-Dawley P7 rat pups were used. GMH was induced by intraparenchymal injection of bacterial collagenase. rIL-19 was administered intranasally 1 hour post-GMH. IL-20R1 CRISPR was administered intracerebroventricularly, or Nrf2 antagonist ML385 was administered intraperitoneally 48 hours and 1 hour before GMH induction, respectively. Neurobehavior, Western blot, immunohistochemistry, histology, and hemoglobin assay were used to evaluate treatment regiments in the short- and long-term. RESULTS: Endogenous IL-19, IL-20R1, IL-20R2, and scavenger receptor CD163 were increased after GMH. rIL-19 treatment improved neurological deficits, reduced hematoma volume and hemoglobin content, reduced ventriculomegaly, and attenuated cortical thickness loss. Additionally, treatment increased ERK, Nrf2, and CD163 expression, whereas IL-20R1 CRISPR-knockdown plasmid and ML385 inhibited the effects of rIL-19 on CD163 expression. CONCLUSION: rIL-19 treatment improved hematoma clearance and attenuated neurological deficits induced by GMH, which was mediated through the upregulation of the IL-20R1/ERK/Nrf2 pathways. rIL-19 treatment may provide a promising therapeutic strategy for the GMH patient population.
Authors: G Gallagher; H Dickensheets; J Eskdale; L S Izotova; O V Mirochnitchenko; J D Peat; N Vazquez; S Pestka; R P Donnelly; S V Kotenko Journal: Genes Immun Date: 2000-10 Impact factor: 2.676
Authors: Stephen Ellison; Khatuna Gabunia; Sheri E Kelemen; Ross N England; Rosario Scalia; James M Richards; A Wayne Orr; Wayne Orr; James G Traylor; Thomas Rogers; William Cornwell; Lisa M Berglund; Isabel Goncalves; Maria F Gomez; Michael V Autieri Journal: Arterioscler Thromb Vasc Biol Date: 2013-08-15 Impact factor: 8.311
Authors: James Richards; Khatuna Gabunia; Sheri E Kelemen; Farah Kako; Eric T Choi; Michael V Autieri Journal: J Mol Cell Cardiol Date: 2014-11-08 Impact factor: 5.000
Authors: Lin Liu; Hui Yuan; Yanhua Yi; Edward C Koellhoffer; Yashasvee Munshi; Fan Bu; Yi Zhang; Zhenggang Zhang; Louise D McCullough; Jun Li Journal: Transl Stroke Res Date: 2018-02-24 Impact factor: 6.829
Authors: Sheng-Peng Liu; Lei Huang; Jerry Flores; Yan Ding; Peng Li; Jun Peng; Gang Zuo; John H Zhang; Jun Lu; Ji-Ping Tang Journal: CNS Neurosci Ther Date: 2019-04-24 Impact factor: 5.243